Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl-2,2,3,3,5,5,6,6-d8)propoxy)quinoline-3-carbonitrile
Purity: ≥99% deuterated forms (d1-d8)
Formula Markup: C26H21Cl2D8N5O3
Formula Weight: 538.49424
CAS Number: 2733145-45-2
Notes: Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib (Item No. 12030) by GC- or LC-MS. Bosutinib is an inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively).{22602,22595} It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others.{22603} Bosutinib inhibits Src-dependent cell proliferation (IC50 = 100 nM) and reverses Src-transformed fibroblasts to a non-transformed morphology when used at a concentration of 1 µM.{22602} It reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models when administered at doses of 30 or 25 mg/kg, respectively, twice per day. Bosutinib (100 mg/kg) also induces complete tumor regression in a K562 mouse xenograft model when administered once per day for five days.{22595}